Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tram Ho

Optometrist Carlsbad, CA Doctor of Optometry

NPI 1245464460 CMS profile 102338

5814 Van Allen Way Ste 146, Carlsbad, CA 92008

Open in the dashboard

General payments

$12,363

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tram Ho of Carlsbad, CA is reported in the CMS Open Payments database as having received $12,363 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,140 33
2024 General $1,218 37
2023 General $601 18
2022 General $427 18
2021 General $169 9
2020 General $4,302 26
2019 General $4,505 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tram Ho
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Tram Ho were reported at $1,140. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Tram Ho Optometrist median Middle half National median
2019 $4,505 $159 $67–$371 $163
2020 $4,302 $72 $29–$165 $114
2021 $169 $125 $46–$292 $132
2022 $427 $162 $66–$374 $149
2023 $601 $177 $72–$406 $160
2024 $1,218 $188 $77–$427 $164
2025 $1,140 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $7,916 14 payments
  2. Bausch & Lomb Americas Inc. $758 29 payments
  3. Alcon Vision LLC $647 19 payments
  4. AbbVie, Inc. $335 12 payments
  5. Shire North American Group Inc $292 11 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $260 13 payments
  7. Optos, Inc. $255 3 payments
  8. Aerie Pharmaceuticals, Inc. $195 12 payments
  9. Tarsus Pharmaceuticals, Inc. $195 7 payments
  10. CooperVision Inc. $179 4 payments
  11. Other $1,331 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,680 6 payments
  2. Food and Beverage $4,290 160 payments
  3. Entertainment $255 3 payments
  4. Travel and Lodging $138 4 payments
Products named General payments · program years 2019–2025
  1. RESTASIS $6,563 10 payments
  2. COMBIGAN $1,300 2 payments
  3. LUMIGAN $1,280 1 payment
  4. INFUSE $390 8 payments
  5. VYZULTA $370 22 payments
  6. XIIDRA $292 11 payments
  7. OCT OPHTHALMOSCOPE Ophthalmology $255 3 payments
  8. NFC-700 $255 3 payments
  9. OCT OPHTHALMOSCOPE Ophthalmology $255 3 payments
  10. PANORAMIC OPHTHALMOSCOPE $255 3 payments
  11. Other $4,084 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Optometry: 120

Drug cost

$2,263

Median for Optometry: $8,864

Branded share of claims

100%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Simbrinza Brinzolamide/Brimonidine Tart Brand 11 $2,263

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $112
$112 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $83
$83 — —
LUMIGAN
  • AbbVie, Inc. $63
$63 — —
MIEBO
  • Bausch & Lomb Americas Inc. $58
$58 — —
Rocklatan
  • Alcon Vision LLC $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record